Pancreatic cancer drug trial halted after safety issues

NCT ID NCT05525286

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tested a new drug called SOT102, alone or with standard chemotherapy, in 31 people with advanced pancreatic cancer. The goal was to find the safest dose and see if it helped shrink tumors. The study was stopped early because of unexpected safety problems that reappeared even after changes were made.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm Neoplasm Metastasis pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Cleveland Clinic Main Campus

    Cleveland, Ohio, 44195, United States

  • Hospital Universitario HM Sanchinarro

    Madrid, Spain

  • Institut Gustave Roussy

    Paris, France

  • Institut Jules Bordet

    Brussels, Belgium

  • Masarykův Onkologický Ústav

    Brno, Czechia

  • Universitair Ziekenhuis Leuven - Campus Gasthuisberg

    Leuven, Belgium

  • VHIO - Vall d'Hebron Institut d'Oncologia

    Barcelona, Spain

  • Washington University School of Medicine in St. Louis

    St Louis, Missouri, 63110, United States